fashion -WSS

fashion

author：entertainment 2025-09-30 16:28:35 - browse：35248

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Biogen joins immunology wave with $1.15 billion acquisition of HI

WSS

Biogen joins immunology wave with $1.15 billion acquisition of HI

As a primary care physician, here's how I hope to partner with AI

Timeline: Special counsel's probe into Trump's handling of classified documents

Questions and answers about ramping up H5N1 bird flu vaccine

Marc Tessier

Fentanyl is making it harder to start addiction treatment

Wikipedia

fashion

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Eyeing GLP

As demand for Covid shots wanes, Moderna seeks its next success

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

In Memoriam: Notable people who died in 2023

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

DIEP, the 'gold standard' of breast reconstruction, is under threat

Hospitals, health systems can help patients avoid medical debt

Continuity nursing helped my family in our darkest PICU moments

Liver decline slowed by off

hotspot

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Addressing health care workers' trauma can help fight burnout

UnitedHealth argues against case alleging wrongful AI care denials

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Eyeing GLP

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

hotspot

hotspot

explore

focus